ELSEVIER

Comprehensive analysis of *APOE* and selected proximate markers for late-onset Alzheimer's disease: Patterns of linkage disequilibrium and disease/marker association

Chang-En Yu [a,b,*], Howard Seltman [c], Elaine R. Peskind [d,e], Nichole Galloway [a], Peter X. Zhou [a],
Elisabeth Rosenthal [f], Ellen M. Wijsman [f,g,h], Debby W. Tsuang [d,e],
Bernie Devlin [i], Gerard D. Schellenberg [a,b,j]

[a] *Geriatric Research, Education, and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108, USA*
[b] *Division of Gerontology and Geriatric Medicine, Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA*
[c] *Department of Statistics, Carnegie Mellon University, Pittsburgh, PA 15213, USA*
[d] *Mental Illness Research, Education, and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108, USA*
[e] *Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA 98195, USA*
[f] *Department of Biostatistics, University of Washington, Seattle, WA 98195, USA*
[g] *Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, WA 98195, USA*
[h] *Department of Genome Sciences, University of Washington, Seattle, WA 98195, USA*
[i] *Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA*
[j] *Division of Neurogenetics, Department of Neurology, and Department of Pharmacology,
University of Washington School of Medicine, Seattle, WA 98195, USA*

Abstract

The ε_4 allele of *APOE* confers a two- to fourfold increased risk for late-onset Alzheimer's disease (LOAD), but LOAD pathology does not all fit neatly around *APOE*. It is conceivable that genetic variation proximate to *APOE* contributes to LOAD risk. Therefore, we investigated the degree of linkage disequilibrium (LD) for a comprehensive set of 50 SNPs in and surrounding *APOE* using a substantial Caucasian sample of 1100 chromosomes. SNPs in *APOE* were further molecularly haplotyped to determine their phases. One set of SNPs in *TOMM40*, roughly 15 kb upstream of *APOE*, showed intriguing LD with the ε_4 allele and was strongly associated with the risk for developing LOAD. However, when all the SNPs were entered into a logit model, only the effect of *APOE* ε_4 remained significant. These observations diminish the possibility that loci in the *TOMM40* gene may have a major effect on the risk for LOAD in Caucasians.
© 2007 Elsevier Inc. All rights reserved.

Keywords: Molecular haplotyping; Apolipoprotein E; Selection; Linkage disequilibrium; Genetic association; Alzheimer disease

Genetic variation in the apolipoprotein E gene (*APOE*) confers risk for both coronary artery disease (CAD) [1] and Alzheimer's disease (AD) [2]. The connection of this gene to CAD is apparent because the ApoE protein, as a component of serum lipoprotein particles, binds to cell surface receptors, mediates lipoprotein uptake, and thus has direct effects on lipid metabolism. In addition, both functional and regulatory variations in *APOE* account for population-level variation in metabolic lipid levels [3]. The connection between ApoE and AD pathogenesis is more obscure. The major *APOE* risk for AD is generally assumed to come from the $\varepsilon_2/\varepsilon_3/\varepsilon_4$ haplotype system, with the ε_4 allele increasing risk for both disorders and the ε_2 allele being protective [4]. However, recent estimates of heritability of AD range from 57% to 78% [5], with ε_4 alleles accounting for only roughly 50% of that heritability.

The $\varepsilon_2/\varepsilon_3/\varepsilon_4$ haplotype system is defined by two nonsynonymous single-nucleotide polymorphisms (SNPs) in *APOE* exon 4. One is a C/T SNP (rs429358) that encodes either arginine (C) or cysteine (T) in ApoE at amino acid 112. The second site defining this haplotype system is a C/T SNP (rs7412), which again encodes arginine (C) or cysteine (T) at ApoE amino acid 158. The allelic compositions of the commonly investigated haplotypes are TT for ε_2, TC for ε_3, and CC for ε_4. The effects of these coding variants on ApoE function are well defined [6]. Regulation of *APOE* expression is controlled by *cis*-acting elements both within the gene and in flanking sequences. The function of these regulatory elements could potentially be influenced by genetic variation. Variation in the 5′ promoter region of *APOE* alters its expression [7,8], and some of these variants may be associated with AD [9], although their impact appears to be minor. In fact, it has proven difficult to provide good estimates of the effect of the 5′ regulatory variation on risk for AD, in part because these SNPs could be in linkage disequilibrium (LD) with ε_4. There are numerous noncoding SNPs within and immediately adjacent to *APOE* that may influence measures of lipid metabolism [10].

Variation just outside of the 3′untranslated region of *APOE* has also been reported to have a minor impact on risk for late-onset Alzheimer's disease (LOAD) [11]. Again, LD potentially confounds interpretation of the association. Downstream regulatory elements include two copies of a multienhancer that control expression of *APOE* in adipocytes, macrophages, and astrocytes (ME1 and ME2) [12,13], two copies of a hepatic control region (HCR1 and HCR2) [14,15] enhancer that control expression in the liver; and a potential brain control region 42 kb from *APOE* that may control expression in brain neurons and microglia [16]. It is unknown whether genetic variation in or near these elements controls *APOE* expression. What of the genes and genetic variants outside but potentially in LD with ε_4 of *APOE*? For example, based on results from cladistic analyses, Templeton [17] argued that variation in *APOC1* causes risk for LOAD. Also unknown is whether there are additional *cis*-elements upstream of the *APOE* promoter that contribute to this risk.

Because of the strong association between the $\varepsilon_2/\varepsilon_3/\varepsilon_4$ variants of *APOE* and the risk for AD, we investigated the LD structure of *APOE* and its surrounding region. Of particular interest are SNPs in potential regulatory regions both within and flanking *APOE* that could modify the risk associated with the $\varepsilon_2/\varepsilon_3/\varepsilon_4$ haplotypes. Also, *APOE* is an excellent model to explore the ability of genome-wide association methods to detect a causative gene when risk for a common disease is determined by a single, monophyletic, common variant therein. To characterize the *APOE*-region LD structure, we genotyped 50 SNPs in and surrounding *APOE*, with particular reference to the ε_2, ε_3, and ε_4 system of alleles. The 550 Caucasian samples genotyped were collected to evaluate the genetic basis of AD. Within *APOE* itself, we report on 21 SNPs that were molecularly phased using the methods reported in Yu et al. [18]. This set of SNPs overlaps substantially with those assayed by Fullerton et al. [19]. Outside of *APOE*, we relied on statistical methods to infer haplotypes or assess LD. In our study

population, we assessed whether selection on ε_4 (or possibly other loci in the region) alters the pattern of LD found in the AD sample relative to that found in the control sample. Significant LD was observed between ε_4 and SNPs spanning 50 kb, a region containing multiple genes. Because of the LD patterns observed, it is difficult to distinguish the impact of ε_4 from highly correlated SNPs in the region. In terms of detecting *APOE* as an AD risk gene, there are numerous SNPs in the region that would detect AD risk, but interestingly, they are not necessarily in *APOE*. In fact, some of the SNPs with the greatest power to detect risk are in the adjacent gene *TOMM40*, while many others much closer to ε_4 would not be useful.

Results

Genotype data of 50 loci (Fig. 1, Supplementary Table 1) in the *APOE* region were generated from a clinical sample of 550 Caucasians. Among the subjects, 193 individuals had a clinical diagnosis of LOAD, 125 individuals had diagnoses of other neurodegenerative disorders, and 232 individuals were controls. For our combined samples, 16 of the 21 *APOE* loci were polymorphic, and 11 of 21 had a minor allele frequency (MAF) >0.05 (Supplementary Table 1). The remaining 29 loci, those outside of *APOE*, were selected to have MAF >0.02 in the samples. After Bonferroni correction for multiple testing, two loci violated Hardy–Weinberg (HW) assumptions in the LOAD sample (SNP 8 [rs6857] and SNP 11 [rs11556505]), a third locus violated HW in the control sample (SNP 1 [rs2965118]), and all three of these loci violated HW when the data were combined to produce the full sample (data not shown). None of the loci within *APOE* violated HW in any of the samples. SNPs in *APOE* were further haplotyped by molecular methods to determine their phases. We used the Allele Discriminating Long and Accurate PCR Haplotyping (ADLAPH) method [18] to produce unambiguous molecular haplotypes for 21 loci in *APOE* (SNPs 17–37, Fig. 1, Supplementary Table 1) from our study samples.

LD pattern within APOE

Genotyping error

Of the 550 individuals genotyped and 1100 haplotypes determined for the 21 *APOE* loci, 12 were singleton haplotypes. We reasoned that some of these singleton haplotypes could result from genotyping error because an error would have a nonnegligible probability of producing a novel, albeit pseudo-haplotype. To address the question of the rate of genotyping error, we performed two analyses, one computational and the other molecular (for details, see Materials and methods). We estimate a per-locus error rate of 0.0003 with an upper 95% confidence interval of 0.0006.

Corrected haplotype distribution

If the *APOE* loci were in linkage equilibrium, then we would expect hundreds of different haplotypes. Because these SNPs fall within a 5300-bp region, we do not expect such a substantial set of haplotypes. Only 35 unique haplotypes are observed in

Fig. 1. SNP map of *APOE* and its surrounding region. A 215-kb genomic section containing nine genes, five *APOE* regulatory elements, and 50 SNPs analyzed in this study is shown. *APOE* and its flanking region are further enlarged. Detailed information of the 50 SNPs is given in Supplementary Table 1.

the distribution, and the distribution is distinctly skewed toward a few common haplotypes (Table 1). Five haplotypes account for over 75% of the haplotype distribution, and 13 haplotypes account for over 95% of the haplotype distribution. The common haplotypes are common in both the LOAD and the control samples, although individual haplotypes clearly differ in frequency (Table 1), especially with respect to the presence/absence of ε_4. After accounting for errors, nine singleton haplotypes occur in the 1100 haplotypes. These singletons are evenly distributed across the samples: for the LOAD sample, the relative frequency of singletons is 0.008; for the control sample, it is 0.006; and for the miscellaneous sample it is 0.008.

In the total sample, 61 chromosomes carry ε_2 on three different haplotypes (Table 1), 741 chromosomes carry ε_3 on 20 different haplotypes, and 298 chromosomes carry ε_4 on 12 different haplotypes. Contrasting the case and control samples (Table 1), the case sample contains 11, 210, and 165 haplotypes bearing $\varepsilon_2/\varepsilon_3/\varepsilon_4$ alleles ($n=386$), respectively, whereas the control sample contains 39, 353, and 72 haplotypes bearing $\varepsilon_2/\varepsilon_3/\varepsilon_4$ alleles ($n=464$).

LD

To analyze the "haplotype-block" structure of *APOE*, as measured by the diversity of the haplotype distribution [20], we restricted the data to the 11 SNPs with MAF >0.02 (see Supplementary Table 1). Results from this analysis are congruent with the restricted distribution of haplotypes in Table 1, suggesting that all but the last locus of *APOE* form a single haplotype block. Analyses for a recombination hot spot were more ambiguous: some runs of Phase 2 found no evidence for a recombination hot spot within these loci (mean posterior likelihood of 1.0 across the region), whereas other runs placed a hot spot in the vicinity of loci 21–23 (rs449647 and rs769446,

mean posterior likelihood of 276.7). The pattern of pair-wise LD in the gene (as measured by a common metric, D' [21]) is compatible with the haplotype structure of the gene (Supplementary Fig. 1), suggesting complete LD for most pairs of loci.

The complementary results of limited haplotype diversity, substantial D', and limited evidence for recombination hot spots suggest that recombination has not been a major evolutionary factor within *APOE*. By contrast, another common measure of pair-wise LD, namely r^2 or Δ^2 [21], is not uniformly large; instead, pair-wise LD varies substantially and is often small (Fig. 2). This measure is also a function of recombination, but is sensitive to a host of other factors, including homoplasy [21,22]. Homoplasy in *APOE* has been demonstrated by Templeton et al., who described the occurrence of a particular mutation on more than one haplotype background in the *APOE* region [22,23].

LD pattern in loci in and surrounding APOE

Pair-wise LD

In this subsection we focus largely on the $\varepsilon_2/\varepsilon_3/\varepsilon_4$ system of alleles, because of their presumed central role in the risk for LOAD. We also use the data from individuals diagnosed with LOAD and contrast those data with those of the controls. Fig. 2 shows the pair-wise LD between the $\varepsilon_2/\varepsilon_3/\varepsilon_4$ system and other loci. Because of the relative rarity of ε_2, we centered the LD analysis on SNP 33, which defines the ε_4 versus ε_3 dichotomy. When measured by r^2, LD between alleles at SNP 33 and alleles outside of *APOE* shows notable variation (Fig. 2), much like the loci in *APOE*. Only one SNP in *APOE* shows a substantial r^2 with SNP 33, SNP 28, whereas a much larger number of SNPs 5' of *APOE* show substantial r^2 (Fig. 2). LD tends to be unpredictable near the $\varepsilon_3/\varepsilon_4$ locus, but seems essentially absent

Table 1
Haplotypes and frequencies for all individuals (All), only individuals diagnosed with LOAD (LOAD), and only individuals who served as controls for LOAD patients (Controls)

No.	Complete haplotype		All		LOAD		Controls	
			Count	Freq.	Count	Freq.	Count	Freq.
1	CCACACTGGGCGATTC**T**C**C**AT	ε_3	241	0.2191	70	0.1814	116	0.2500
2	CCACACTTCGCGGTTC**T**C**C**AT	ε_3	213	0.1936	53	0.1373	107	0.2306
3	CCACACTTCGCAGTTC**C**C**C**AT	ε_4	204	0.1855	111	0.2876	52	0.1121
4	CCACTCTTCGCGGTTC**T**C**C**AT	ε_3	92	0.0836	23	0.0596	43	0.0927
5	CCACACTGGGCGATTC**T**C**C**AC	ε_3	91	0.0827	26	0.0674	37	0.0797
6	CCACACTGGGCGGTTC**C**C**C**CT	ε_4	59	0.0536	34	0.0881	14	0.0302
7	CCACTCTGGGCGGTTC**T**C**T**AT	ε_2	40	0.0364	8	0.0207	25	0.0539
8	CCACACCTCGTGGTTC**T**C**C**AT	ε_3	33	0.0300	13	0.0337	14	0.0302
9	CCACTCTGGGCGATTC**T**C**C**AT	ε_3	26	0.0236	9	0.0233	15	0.0323
10	CCACACCGGGCGGTTC**T**C**T**AT	ε_2	18	0.0164	3	0.0078	11	0.0237
11	CCACACCTGGCAGTTC**C**C**C**AT	ε_4	17	0.0155	9	0.0233	2	0.0043
12	CCACACCGGGCGATTC**T**C**C**AT	ε_3	10	0.0091	4	0.0104	5	0.0108
13	CCACACCTCGCGGTTC**T**C**C**AT	ε_3	9	0.0082	3	0.0078	5	0.0108
14	CCACACTGGGCGGTTC**C**C**C**AT	ε_4	5	0.0046	4	0.0104	0	0
15	CCACACTTCGCGGGTC**T**C**C**AT	ε_3	4	0.0036	1	0.0026	3	0.0065
16	CCACACTGCGCGGTTC**T**C**C**AT	ε_3	4	0.0036	1	0.0026	2	0.0043
17	CCACACCGGGCGATTC**T**C**C**AC	ε_3	3	0.0027	1	0.0026	2	0.0043
18	CCACACTTGGCAGTCC**C**C**C**AT	ε_4	3	0.0027	1	0.0026	2	0.0043
19	CCACACTGGGCGGTTC**T**C**T**AT	ε_2	3	0.0027	0	0	3	0.0065
20	CCACACTTGGCAATTC**T**C**C**AT	ε_3	3	0.0027	1	0.0026	0	0
21	CCACTCTGGGCGGTTC**T**C**C**AT	ε_3	3	0.0027	2	0.0052	0	0
22	CCACTCCTCGCGGTTC**T**C**C**AT	ε_3	2	0.0018	0	0	2	0.0043
23	CCGCTCTTGGCGGTTC**C**C**C**AT	ε_4	2	0.0018	1	0.0026	1	0.0022
24	CCACACTTCGCGGTTC**T**C**T**CAT	ε_3	2	0.0018	2	0.0052	0	0
25	CCGCTCTGGGCGGTTC**C**C**C**AT	ε_4	2	0.0018	1	0.0026	0	0
26	CCACACCGGGCGGTTC**C**C**C**AT	ε_4	2	0.0018	2	0.0052	0	0
27	CCACACTGGGCGGTTC**T**C**C**AT	ε_3	1	0.0009	0	0	1	0.0022
28	CCACTCCGGGCGGTTC**T**C**C**AT	ε_3	1	0.0009	0	0	1	0.0022
29	CCGCACTTGGCGGTTC**C**C**C**AT	ε_4	1	0.0009	0	0	1	0.0022
30	TCACACTGGGCGGTTC**T**T**C**AT	ε_3	1	0.0009	1	0.0026	0	0
31	CCACACTTCGCAGTTC**C**C**C**AT	ε_4	1	0.0009	1	0.0026	0	0
32	CCACACTGGGCGGTTC**C**C**C**AC	ε_4	1	0.0009	1	0.0026	0	0
33	CCACTCTTGGCGGTTC**C**C**C**AT	ε_4	1	0.0009	0	0	0	0
34	CCACTCCTCGTGGTTC**T**C**C**AT	ε_3	1	0.0009	0	0	0	0
35	CCACACTTCGTGGTTC**T**C**C**AT	ε_3	1	0.0009	0	0	0	0

"All" contains other samples in addition to LOAD and Controls. Embedded in the 21-locus (Fig. 1 and Supplementary Table 1, SNP 17-37) haplotypes, in bold, are the 2-locus haplotypes that encode the $\varepsilon_2/\varepsilon_3/\varepsilon_4$ system of alleles.

at more substantial distances (Supplementary Table 1, Fig. 2). The pattern is similar for both the LOAD and the control samples. When LD is measured by $|D'|$ (Fig. 2), however, the values for most loci around SNP 33 are large (close or equal to 1) and are predictably small only at substantial distances from SNP 33 (Supplementary Table 1, Fig. 2). Again the pattern is similar for both the LOAD and the control samples. We do not report hot-spot analysis for the larger region because we could not discern a consistent pattern in the results; it appears that numerous regions show some evidence for elevated recombination rates.

Tag SNPs

To summarize multivariate LD across these loci, as well as to identify tag SNPs, we used the hierarchical cluster methods proposed by Rinaldo et al. [20]. Tag SNPs were selected using a bound of 0.8. Cluster analysis identifies only a few substantial clusters and shows similar clustering features for both the LOAD and the control samples (Supplementary Fig. 2). SNPs spanning roughly 50 kb and covering *APOC4, APOC2,* and *CLPTM1* show substantial joint LD (SNPs 41–50 in Supplementary Fig. 2). This cluster, however, has no noteworthy correlation with SNPs 33 and 35, which define the $\varepsilon_2/\varepsilon_3/\varepsilon_4$ system. In terms of clustering by LD, SNPs 33 and 35 do not fall in the same cluster regardless of whether the LOAD or control samples were evaluated. Not only are SNPs 33 and 35 largely independent, they do not cluster strongly with other SNPs in *APOE*, with the exception of SNP 28, which clusters with SNP 33. Interestingly, SNP 33 clusters tightly with SNPs in *TOMM40*, especially SNPs 10–12 (Fig. 1), which are separated from SNP 33 by roughly 16 kb. SNPs 10 and 11 occur in *TOMM40* exons 3 and 4, respectively. SNP 35, defining the ε_2 versus ε_3 dichotomy, shows modest clustering with SNP 5, roughly 38 kb away, in the second intron of *PVRL2*.

HapMap SNPs

To contrast our results with data from HapMap, we downloaded the data from Release 21a (Phase II Jan07 on NCBI B35

Fig. 2. Pair-wise LD between SNP 33 alleles (defining $\varepsilon_3/\varepsilon_4$ dichotomy) and all other loci across the region (except SNP 35, which defines the $\varepsilon_2/\varepsilon_3$ dichotomy). Left and right show different disequilibrium measures (r^2 versus $|D'|$) and top and bottom contrast the LOAD sample versus the sample of control individuals.

assembly, dbSNP b125; see HapMap at www.hapmap.org). This version contains 219 SNPs spanning the same region that we evaluated. Notably, neither SNP 33 (rs429358) defining the $\varepsilon_3/\varepsilon_4$ dichotomy nor SNP 35 (rs7412) defining the $\varepsilon_2/\varepsilon_3$ dichotomy has genotypes in the CEU population of this version of HapMap. Nonetheless, genotypes for two other SNPs that we have previously shown to be highly correlated with SNP 33 ($r^2 > 0.5$) are contained therein, namely SNPs 8 (rs6857) and 16 (rs10119), as well as other SNPs that are more moderately correlated. Because genotypes of SNPs 8, 16, and 33 are available in both Yoruba (YRI) and Japan (JPT) samples in HapMap, we evaluated these SNPs' correlation in the two ethnic groups. Results indicated that both SNPs 8 and 16 do not correlate well with SNP 33 ($r^2 = 0.0$ and 0.029, respectively, for SNPs 8 and 16 in YRI and $r^2 = 0.08$ and 0.101 in JPT). Therefore, LD patterns in this region do not appear to be consistent across the different ethnic groups; although, since SNP 8 was one of the SNPs that deviated from Hardy–Weinberg equilibrium, we cannot exclude the possibility that there are as yet unrecognized genotyping artifacts, which could affect this conclusion.

Notably, the HapMap CEU data recapitulate the pattern of LD and clustering in Caucasians shown in Supplementary Fig. 2. Strong clustering emerges over a 50-kb region that contains the genes *APOC1, APOC2, APOC4*, and *CLPTM1*, while the roughly 60-kb proximal region shows no substantial clustering (data not shown). Clustering the HapMap CEU SNPs using H-clust reveals another SNP that should be highly correlated with

SNP 33, specifically rs2075650, which has an r^2 of roughly 0.85 with SNP 8. Tag SNP selection using H-clust and the HapMap data always draws an SNP highly correlated with SNP 33, for a wide range of stringency of SNP selection, even to $r^2 = 0.20$ (data not shown). Therefore a genome-wide or local association scan built from HapMap data would very likely detect association with LOAD for regional SNPs, assuming the scan were adequately powered.

Disease marker association

APOE and ε_4 count

As has been demonstrated for many different samples, the distribution of ε_4 alleles (Table 2) differs substantially between AD and control samples ($\chi^2 = 78.6605$, $df = 2$, $p \leq 2.2 \times 10^{-16}$). When evaluated by sex, the distribution of ε_4 alleles did not

Table 2
AD status versus count of ε_4 alleles

Sample	Count of ε_4 alleles		
	0	1	2
All with AD	58 (30.9)	105 (54.4)	30 (15.5)
All controls	162 (61.8)	68 (29.3)	2 (0.9)
Women with AD	32 (30.9)	55 (54.4)	15 (15.5)
Women controls	91 (61.8)	45 (29.3)	2 (0.9)
Men with AD	26 (30.9)	50 (54.4)	15 (15.5)
Men controls	71 (61.8)	23 (29.3)	0 (0.9)

differ between men and women diagnosed with AD ($\chi^2 = 0.23$, $df = 2$, $p = 0.89$) or between men and women in the control samples ($\chi^2 = 2.01$, $df = 1$, $p = 0.16$). Analysis of age at AD diagnosis, performed using a Cox proportional hazards model, shows time to diagnosis is strongly dependent on ε_4 count ($\beta = -1.07$, SE = 0.111, $z = 9.67$, $p \sim 0.0$). Survival analysis models with gender and ε_4/gender interaction reveal no additional significant covariates.

Other SNPs in APOE

Within *APOE*, 11 SNPs were sufficiently polymorphic for inference using measured haplotype analysis (MHA) [24]. MHA uses inferred evolutionary relationships among haplotypes, specified in the form of a cladogram, to structure the tests of association. The network relating all haplotypes with one-step mutations is given in Fig. 3a; only one haplotype is not connected in this network, and it differs from three other haplotypes by two mutational steps. Evolutionary rules [23] break the cycles in the network to produce a cladogram (Fig. 3b) of haplotypes connected by one-step mutations. The cladogram has the plausible feature of clustering ε_4- and ε_3-containing haplotypes, but the three ε_2-containing haplotypes are implausibly separated in the evolutionary space. The latter is of little concern given the modest impact of ε_2, and in fact, the results do not differ if the haplotypes are grouped (results not shown). We simplify the cladogram for statistical inference by consolidating rare haplotypes with more common haplotypes, because the impact on risk of rare haplotypes—even if it were substantially different from adjoining haplotypes—could not be distinguished statistically.


Fig. 3. (a) Network and (b) cladogram representing relationships between 11-locus haplotypes of *APOE*.


Fig. 4. Results of association analyses for AD status versus individual SNP genotypes, with or without taking count of ε_4.

We also performed a cladistic analysis using eHap for $\varepsilon_2/\varepsilon_3/\varepsilon_4$ haplotypes as a simple contrast of haplotypes on the cladogram $\varepsilon_4–\varepsilon_3–\varepsilon_2$. When ε_4 is contrasted with ε_3, while estimating the effect of ε_2 as a nuisance parameter, the contrast is highly significant, and thus the nodes remain distinct ($\chi^2 = 79.75$, $df = 1$, $p \sim 0$). When ε_2 is contrasted with ε_3, while estimating the effect of ε_4 as a nuisance parameter, the contrast is not quite significant, and thus the nodes collapse for purposes of estimation ($\chi^2 = 3.48$, $df = 1$, $p = 0.062$). The latter result is typical for samples of this size; the small protective effect of ε_2 is evident in the odds, but it is not significant. The odds of AD for the combined set of ε_2 and ε_3 haplotypes is roughly fivefold less than that for ε_4.

SNPs inside/outside of APOE

Using MHA we found a cluster of high-risk haplotypes, all of which contain ε_4 alleles, and another cluster of low-risk haplotypes that contain either ε_2 or ε_3 alleles. Thus, for these data and MHA, we find no evidence that SNPs elsewhere in *APOE*, such as in its regulatory region, have a significant impact on risk for AD. We would have reached the same conclusions fitting AD status to two SNP models in which one SNP is always represented by the ε_4 allele count as we show now.

We imagine two scenarios, one in which one analyzes association with AD status without knowledge of ε_4 status and one in which one appropriately conditions on ε_4 count. Forty SNPs were informative enough in the AD and control samples to produce valid tests (see Supplementary Table 1). It is apparent that, in the absence of information about ε_4 count, many loci in the region show significant association with AD status even after Bonferroni correction (Fig. 4). In fact, of the 40 informative loci, 28 SNPs have $p \leq 0.05$ and 12 are less than the Bonferroni cutoff of 0.00125. Multiple SNPs in *TOMM40* and *APOE*, and at least one SNP in *LU, PVRL2, APOC1, APOC4*, and *CLPTM1*, were associated with AD risk. In our sample, the association with AD was significant ($p < 0.05$) for *APOE* SNPs −491 (SNP 21) and +113 (SNP 25), but not for −427 (SNP 23),

Table 3
Number of AD and control subjects by TOMM40 SNP 10 and APOE ε₄ genotypes

TOMM40, SNP 10	APOE			
	Cases		Controls	
	CC	CT or TT	CC	CT or TT
CC	24	8	1	9
CT or TT	5	144	0	217

−219 (SNP 24), or +5361 (SNP 37). However, when ε₄ count is incorporated into the model and after Bonferroni correction, no locus has a significant, independent effect on AD status (Fig. 4).

MHA for logical units across this region, such as genes, produces the same conclusion (data not shown). In general, when MHA is performed without conditioning on ε₄ count, certain portions of the cladogram do not "collapse" into a single node, suggesting some haplotypes were different in their impact on AD risk. However, when ε₄ count is introduced as a covariate, the cladograms always collapsed into a single node, which is consistent with the null hypothesis that haplotypes have no impact on risk for AD.

TOMM40 SNP 10 versus APOE ε₄

Of these results, the association of SNPs in *TOMM40* with AD, especially SNP 10 (rs157581), is arguably most intriguing. The C allele of SNP 10 in *TOMM40* is in very strong LD with the C allele of SNP 33 in *APOE*, which defines the ε₄ allele. The correspondence is so strong (Table 3) that one might wonder how the statistical models favor ε₄ as the risk allele. But there is information to distinguish the effects. For an additive (allele) logit model, the odds ratio for the presence of ε₄ versus the status of AD is estimated to be 4.1, whereas the odds ratio for AD status using the alleles of SNP 10 is 2.88. Moreover, when variables representing both SNPs are entered into the logit model, either with or without an additional interaction term between the two SNPs, only the effect of *APOE* ε₄ count is significant.

Perhaps the effects of the *TOMM40* SNP 10 alleles are not additive, but they are expressed recessively. Consider individuals who are doubly homozygous for C alleles (at *TOMM40* and *APOE*), homozygous for C alleles only at SNP 35 of *APOE*, homozygous for C alleles only at SNP 10 of *TOMM40*, or homozygous for neither. The case/control counts for these multilocus genotype classes are 24/1, 5/0, 8/9, and 144/217. From the contrast of 5/0 to 8/9, it appears that risk solely or predominantly arises from ε₄ homozygotes, because the SNP 10 CC homozygotes are about equally likely to occur in case and control individuals who are not homozygous for ε₄.

Discussion

The ε₂/ε₃/ε₄ system of alleles in *APOE* appears to play a crucial role in risk for LOAD. In fact, as much as 50% of the population risk for LOAD could be attributable to ε₄ alone [4]. For the past decade, however, other loci in *APOE* and surrounding genes have also been associated with risk for LOAD.

For instance, variation in the 5′ region of *APOE* has been shown to alter the expression of the gene, to produce population-level variation in metabolic lipid levels [3], and to have a weak impact on risk for LOAD [9]. Among the *APOE* promoter SNPs, the −491 A, −427 C, and −219 T variants have a higher frequency in AD cases than in controls in some, but not all, studies [25–30]. Nonetheless, the impact of other loci has proven difficult to define because of their known or potential LD with SNP 33, which defines the ε₃/ε₄ dichotomy. Surprisingly, only a few studies have undertaken a comprehensive assessment of the patterns of LD in the *APOE* region [31], and none of those studies have used molecular methods to ensure the accuracy of phased chromosomes. We provide a comprehensive assessment of LD by using molecular haplotyping to phase 21 SNPs in *APOE* itself [18] and complementary statistical methods for an additional 29 SNPs surrounding *APOE*.

In our Caucasian sample, the association with AD was significant for *APOE* promoter SNPs −491 (SNP 21) and +113 (SNP 25). However, when ε₄ count is incorporated into the model and after Bonferroni correction, no locus has a significant, independent effect on AD status. As for SNPs outside of *APOE*, one locus in our comprehensive analysis, a synonymous SNP in the *TOMM40* gene, accounts for increased risk for developing AD. Again, when ε₄ status is accounted for in the model, no single SNP explains a significant portion of the risk. Therefore, while tight LD between *APOE* and *TOMM40* raises the possibility that the latter locus may contribute to the risk for developing AD, ε₄ remains the most likely LOAD allele in the region.

Within *APOE* itself, we genotyped 21 previously reported SNPs, but found only 16 to be polymorphic in our samples of 550 individuals, of which 11 had MAF > 0.02. These 11 SNPs cover 4802 bp of genomic sequence. Thus, within *APOE*, an SNP with MAF > 0.02 occurs every 437 bp, on average. This density of SNPs is slightly higher than what is observed, on average, from completely sequenced genes in general [32]. For the ε₂/ε₃/ε₄ system of alleles, we found that ε₄ is embedded in 12 different haplotype backgrounds; ε₃ is embedded in 20 different haplotype backgrounds; while ε₂ is embedded in only 3 backgrounds (Table 1). Because there were 298 haplotypes bearing ε₄ and 741 bearing ε₃, there is proportionately more variety in ε₄-bearing haplotypes than in ε₃-bearing haplotypes (on average, 24.8 copies per ε₄ haplotype versus 37.1 copies per ε₃ haplotype). This observation is consistent with the conjecture that ε₄ is ancestral to ε₃, based on analyses of other primates [33], all of which carry the ε₄ allele. Nonetheless, the fact that ε₃ is now far more common in human populations worldwide has led to the conjecture that ε₃ has been under positive selection since its introduction in early humans [19]. Consistent with our observation that variation in *APOE* is at least as large as that seen in other genes, however, Fullerton et al. [19] could find no statistical evidence for selection, which would be expected to reduce regional variation.

If "haplotype block" structure is measured by the distribution of haplotypes, our analyses suggest most of the SNPs in *APOE* exist in a single block. In fact, only five haplotypes account for

over 75% of the chromosomes in the sample. On the other hand, if LD is measured pair-wise by r^2 (Supplementary Fig. 1), or even by multivariate assessment of LD based on pair-wise r^2 (Supplementary Fig. 2), our analyses suggest much less LD. This result suggests that this contrast underscores the superiority of assessing multivariate LD, such as by analysis of the distribution of haplotypes.

To make the drawback of pair-wise LD more concrete, we offer a simple example. Imagine that there exists (or historically existed) a population in which there are five linked SNPs, with alleles named "1" and "2". Alleles at the loci are independent and thus all 32 possible haplotypes occur. From this population a sample is drawn to found a new population. The sample contains only 4 haplotypes (Table 4), each of which occurs with probability 0.25. As can be seen in Table 4, while the haplotype distribution is limited, the founder haplotypes set up a peculiar pattern of pair-wise LD, regardless of the measure of LD used (see Devlin and Risch [21] for discussion). Pairs of adjacent loci are pair-wise independent, while more distant pairs of loci are either in absolute LD or independent. While artificial, this scenario makes two points: pair-wise LD can fail to capture higher level LD, even in very simple instances (known in statistics as Simpson's paradox) and comparisons of pair-wise LD across and within genomic regions potentially confound an evolutionary parameter of interest, namely the recombination rate, with founder effect. This confounding will be most important for recently founded populations, but we suspect it is also important for other populations, such as those of European and Asian decent.

Our experimental design oversamples for individuals diagnosed with LOAD. Devlin and Risch [21] and Devlin et al. [34] have shown that various measures of pair-wise LD can be biased in the face of this oversampling. Due to this bias, one might expect the patterns of LD to differ substantially between the LOAD and the control samples. Instead we see similar patterns

for both samples (Fig. 2, Supplementary Figs. 1 and 2), although the controls show somewhat stronger LD. These patterns are probably due to the fact that SNPs 33 and 35, defining the $\varepsilon_2/\varepsilon_3/\varepsilon_4$ system, are not in high LD with many other genotyped SNPs in the region. If they were tightly linked, we would expect more divergent patterns in the two samples.

As described in more detail by North et al. [31], the pattern of LD in the region has implications for the power to detect the association between $\varepsilon_2/\varepsilon_3/\varepsilon_4$ and LOAD, assuming that this system of alleles was not genotyped but other SNPs in the region were. Two cross-currents complicate predictions about detection. As seen in Fig. 2, LD as measured by r^2 is not large, yet this is the natural measure for power due to its direct connection to the χ^2 statistic [35]. On the other hand, the strength of the association between LOAD and the $\varepsilon_2/\varepsilon_3/\varepsilon_4$ system is substantial. Assuming an odds ratio for ε_4 versus ε_3 in the LOAD versus control samples of about 2.0 and assuming that the frequency of ε_4 in the population is 0.12, to detect the association with ε_4 with 80% power at a significance level of 0.05 would require roughly 100 individuals diagnosed with LOAD and an equal number of controls. To detect the ε_4 association by genotyping a locus in LD would require samples of size of roughly N/r^2 [35]. Even if r^2 were as small as 0.1, the required sample size for 80% power under these assumptions is only about 1000 cases and controls.

Scanning the region within and around *APOE*, there is only one set of SNPs that show large LD, as measured by r^2, with the $\varepsilon_2/\varepsilon_3/\varepsilon_4$ system of alleles (Fig. 2, Supplementary Figs. 1 and 2). These loci fall in *TOMM40*, roughly 15 kb 5′ of *APOE*. SNPs within this region (SNPs 8–12, Fig. 1) have some of the strongest genetic associations with the risk for AD in our Caucasians AD samples (Supplementary Table 1). *TOMM40* encodes a subunit of the multisubunit translocase of the outer mitochondrial membrane, the TOM complex [36], which plays a role in protein transport into mitochondria. In fact, the TOM40 protein forms the critical pore and actively sorts protein for submitochondrial locations [37]. Because structural abnormalities and oxidative stress of the mitochondria are known to increase risk for AD and because defects in mitochondrial energy metabolism have been observed in AD [38–41], the possibility exists that part of the liability for LOAD commonly ascribed to ε_4 might be caused by *TOMM40* on the basis of its strong LD. However, contrasting the effects of all 50 loci in this region on the risk of AD, with and without conditioning on ε_4 status, our findings diminish the possibility that *TOMM40* or other loci near *APOE* may have a major effect on the risk of LOAD in Caucasians.

Our results support the idea that associations can be detected at SNPs near a complex disease gene when the causative mutations are essentially monophyletic, as for *APOE* ε_4. However, a high density of SNPs will be necessary to ensure the detection of such association with causative disease changes. Our study provides an excellent scenario to support this point of view. Because *TOMM40* has functional implications in AD pathogenesis and it shows strong genetic association with LOAD, if the *APOE* ε_4-defining SNP (SNP 33 [rs429358]) was not genotyped and analyzed in the study,

Table 4
Heuristic example of the failure of pair-wise LD to capture higher level LD

Haplotype	Loci				
	a	b	c	d	e
1	1	1	1	1	1
2	1	2	1	2	1
3	2	1	2	1	2
4	2	2	2	2	2
Loci	Disequilibrium				
	a	b	c	d	e
a		0	1	0	1
b	0		0	1	0
c	1	0		0	1
d	0	1	0		0
e	1	0	1		

The four haplotypes occur with equal probability, 0.25, in the population. Pair-wise LD, as measured by r^2 (but true also of any measure of LD reviewed by Devlin and Risch [21]), fluctuates in a peculiar pattern and fails to capture the higher level features of LD, namely that only 4 of the possible 32 haplotypes occur in the population.

one could have mistakenly selected *TOMM40* as the candidate gene for LOAD. Thus, enormous research effort could be in vain by studying the incorrect genes. Moreover, our study further demonstrates that haplotype-based analysis can provide additional information with respect to tests of significance and fine localization of the most critical causative variants.

Materials and methods

Study samples

Human subjects were collected by the University of Washington Alzheimer's Disease Research Center. All were unrelated individuals of European ancestry. The samples consisted of 193 individuals diagnosed with LOAD, 232 similarly aged subjects with no cognitive impairment, and 125 individuals with various other neurodegenerative disorders, including possible LOAD, dementia with Lewy bodies, Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia.

SNPs genotyped

Fifty potentially variable sites were genotyped in this study, as mapped in Fig. 1. Twenty-one of these SNPs fall in *APOE* and its potential 5′ regulatory region, which covers roughly 5300 bp of genomic sequence, and were genotyped by primer extension assays using the SNuPE assay reagents [18]. SNPs within *APOE* were selected according to the study of Fullerton et al. [19] and described in detail previously [18]. An additional 29 SNPs were chosen to evaluate other genes/genomic elements that were proximate to *APOE* and could plausibly affect risk for LOAD. Sixteen fall within roughly 114 kb 5′ of *APOE*; the remaining 13 fall within roughly 82 kb 3′ of *APOE* (Fig. 1, Supplementary Table 1). These proximate SNPs were genotyped by TaqMan allele discrimination assays (Applied Biosystems, CA, USA).

Genotyping error

By our computational analysis, we wished to estimate the probability that a single error introduced into a naturally occurring haplotype—defined as a haplotype that occurs at least twice in the sample—would produce a pseudo-haplotype instead of a naturally occurring haplotype. To estimate this probability p_{SH} we iteratively performed the following experiment: (1) randomly draw a haplotype from the distribution of naturally occurring haplotypes, (2) randomly select one of the $L = 11$ polymorphic loci, (3) change the selected base pair to its complement, and (4) determine whether the resultant haplotype was also in the naturally occurring haplotype list. Performing this experiment a million times yielded the estimated probability of producing a pseudo-haplotype by error, which was $p_{SH} = 0.792$. If this experiment were performed using all variable loci, $L = 16$, it would yield a slightly higher probability estimate; if more than one locus were altered on a haplotype, the estimated probability would be substantially larger.

To determine if any of the singleton haplotypes were pseudo-haplotypes, we started with the genomic DNA from the 12 samples containing singleton haplotypes. These samples were scored by direct sequencing instead of primer extension reactions, which allowed us to generate completely independent results from the previous experiments. Among the 12 samples, 9 were consistent with the previous results. Three subjects, however, showed inconsistency at a single SNP. Two of these errors were clerical, occurring when the data were entered by hand; the other error was due to a rare SNP that disrupted one of the priming sites for primer extension reaction. Thus from our data we would estimate the probability of drawing a singleton haplotype with a single error, $p_{E,S}$, to be $3/1100 \approx 0.00272$, with 6 of 12 singleton chromosomes representing an upper 96% confidence interval on the number of errors, given binomial sampling, to give a 96% upper confidence interval of ≈ 0.00544. Two of these errors occurred for SNPs with MAF > 0.02.

If we assume that errors are independent across loci on a haplotype and across haplotypes, it is straightforward to develop an estimator for the probability ε of an error on an individual SNP, namely $\varepsilon \approx p_{E,S}/(L \times p_{SH})$. Taking

$L = 11$, and plugging in our estimates obtained from the molecular and computational analyses, we estimate a per-locus error rate of 0.00031. Two observations also follow from these calculations: the probability of haplotypes, natural or pseudo, with two or more errors on them is negligible, and roughly four other haplotypes are expected to be erroneous, but they mimic naturally occurring haplotypes and cannot be corrected.

Molecular haplotyping methods

To produce molecular haplotypes for 21 loci in *APOE* from our study samples, we used the ADLAPH method described in Yu et al. [18]. Briefly, ADLAPH combines allele-discriminating primers and long-range PCR amplification to amplify long genomic fragments from only one of the two chromosome homologues of a particular subject. The phase-separated long-range PCR product is then genotyped by standard methods to yield one haplotype. Contrast with the original diploid genotypes is then carried out to provide the complementary haplotype. Comparisons between molecular and computational haplotyping methods have been previously discussed in our other studies [18,42]. For a small region with tight LD (such as the entire *APOE* gene), the computational methods do not differ substantially in their estimates of haplotype distributions [18]. However, when a larger region without tight LD was analyzed, the molecular haplotypes increased the linkage information by as much as 9% over the unphased SNPs [42]. In this example, marker phase resolution via molecular haplotyping led to modest increases in the evidence for linkage in these data. Yet, larger gains may be possible in datasets with greater inherent phase ambiguity, such as in studies with larger numbers of markers, more polymorphic markers, or weaker LD between markers.

Statistical methods

Haplotype frequencies comprising SNPs outside of *APOE* were inferred by using maximum likelihood as implemented in the eHap program [43] (see CompGen Web site: http://wpicr.wpic.pitt.edu/WPICCompGen/). To account for the phase-known haplotypes of *APOE*, we recoded haplotypes as alleles and the eHap program was specifically tailored to account for absolute haplotypes. Single SNP and haplotype-based statistical analyses were performed using the eHap program [43]. eHap relates haplotypes to phenotypes by using likelihood techniques that account for haplotype uncertainty. The program offers a flexible set of hypothesis tests, including goodness-of-fit or omnibus tests and specified contrasts of association between haplotypes and phenotypes.

To estimate haplotypes at all 50 loci and to infer regions of greater than expected frequency of recombination (recombination hot spots), we used Phase (Version 2.0) [44–46]. Phase uses Bayesian methods for inference, based on the assumption that the evolutionary relationships among haplotypes can be imputed from their degrees of similarity. LD block structure was defined in the sense of Rinaldo et al. [20], namely blocks are regions of limited haplotype diversity. To identify blocks, we used Entropy Blocker (CompGen). Using output from Phase, its algorithm identifies those regions that exhibit substantial multilocus disequilibrium, ranging over a substantial number of SNPs, while allowing one or more SNPs to separate blocked regions or adjacent blocks. The model computes the likelihood of the data minus a penalty for model complexity, using the criteria that blocks should have very low haplotype diversity and that the LD with SNPs outside a block should be small. Entropy Blocker was also used to visualize pair-wise LD.

To select "tagging SNPs," we used H-clust [20] (CompGen). The algorithm in H-clust identifies highly correlated sets of SNPs and chooses an SNP within each correlated cluster to represent the cluster. Input data are multilocus genotypes, which are transformed into a per-locus count of the minor alleles (0, 1, or 2). This transformed matrix of multilocus genotypes is then itself transformed into a correlation matrix from which clusters of SNPs are identified by hierarchical clustering. Within each cluster, the SNP that is most highly correlated with other SNPs in the cluster is chosen as its tag SNP.

We use MHA [24] to evaluate haplotype associations with AD. MHA uses inferred evolutionary relationships among haplotypes, specified in the form of a cladogram (an unrooted evolutionary tree), to structure the tests of association.

Procedures for MHA are described in Templeton et al. [24] and Seltman et al. [43]. To perform this cladistic analysis, the cladogram is divided into subgroups (clades): individual haplotypes occurring as leaves (terminal nodes) on the tree represent 0-step clades; 1-step clades are produced by moving backward one mutational step from the 0-step clades toward internal nodes and then this procedure is repeated to produce the 2-step clades and so forth. For inference, a series of 1-degree-of-freedom tests is performed in a sequential fashion based on the clades, from 0-step clades onward. At each step in the algorithm, a full model is fit. The full model is the same within each step, but changes between steps, conditional upon the results of the previous step, with the goal of testing whether clades differ in their impact on phenotype, in this case risk of AD. MHA has been used in a variety of settings [47–50].

Results for MHA are reported in detail only for the molecularly haplotyped SNPs in *APOE*. For SNPs outside of *APOE*, we performed MHA for SNPs occurring in logical clusters, such as genes, and we fit additive logit models based on the count of alleles at the locus of interest; for both kinds of analyses, we "conditioned" on ε_4 genotype by entering the count of ε_4 alleles as a covariate in the models.

Acknowledgments

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.ygeno.2007.02.002.

References

[1] Y. Song, M.J. Stampfer, S. Liu, Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease, Ann. Intern. Med. 141 (2004) 137–147.

[2] G.D. Schellenberg, I. D'Souza, P. Poorkaj, The genetics of Alzheimer's disease, Curr. Psychiatry Rep. 2 (2000) 158–164.

[3] R. Frikke-Schmidt, C.F. Sing, B.G. Nordestgaard, A. Tybjaerg-Hansen, Gender- and age-specific contributions of additional DNA sequence variation in the 5′ regulatory region of the APOE gene to prediction of measures of lipid metabolism, Hum. Genet. 115 (2004) 331–345.

[4] L.A. Farrer, et al., Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium, JAMA 278 (1997) 1349–1356.

[5] N.L. Pedersen, S.F. Posner, M. Gatz, Multiple-threshold models for genetic influences on age of onset for Alzheimer disease: findings in Swedish twins, Am. J. Med. Genet. 105 (2001) 724–728.

[6] J. Raber, Y. Huang, J.W. Ashford, ApoE genotype accounts for the vast majority of AD risk and AD pathology, Neurobiol. Aging 25 (2004) 641–650.

[7] M.J. Artiga, et al., Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene, FEBS Lett. 421 (1998) 105–108.

[8] M.C. Ramos, et al., Neuronal specific regulatory elements in apolipoprotein E gene proximal promoter, NeuroReport 16 (2005) 1027–1030.

[9] S.M. Laws, E. Hone, S. Gandy, R.N. Martins, Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription, J. Neurochem. 84 (2003) 1215–1236.

[10] J.H. Stengard, et al., Contributions of 18 additional DNA sequence variations in the gene encoding apolipoprotein E to explaining variation in quantitative measures of lipid metabolism, Am. J. Hum. Genet. 71 (2002) 501–517.

[11] K.K. Nicodemus, et al., Comprehensive association analysis of APOE regulatory region polymorphisms in Alzheimer disease, Neurogenetics 5 (2004) 201–208.

[12] S. Grehan, E. Tse, J.M. Taylor, Two distal downstream enhancers direct expression of the human apolipoprotein E gene to astrocytes in the brain, J. Neurosci. 21 (2001) 812–822.

[13] S.J. Shih, et al., Duplicated downstream enhancers control expression of the human apolipoprotein E gene in macrophages and adipose tissue, J. Biol. Chem. 275 (2000) 31567–31572.

[14] W.S. Simonet, N. Bucay, S.J. Lauer, J.M. Taylor, A far-downstream hepatocyte-specific control region directs expression of the linked human apolipoprotein E and C-I genes in transgenic mice, J. Biol. Chem. 268 (1993) 8221–8229.

[15] N.S. Shachter, Y. Zhu, A. Walsh, J.L. Breslow, J.D. Smith, Localization of a liver-specific enhancer in the apolipoprotein E/C-I/C-II gene locus, J. Lipid Res. 34 (1993) 1699–1707.

[16] P. Zheng, L.A. Pennacchio, W. Le Goff, E.M. Rubin, J.D. Smith, Identification of a novel enhancer of brain expression near the apoE gene cluster by comparative genomics, Biochim. Biophys. Acta 1676 (2004) 41–50.

[17] A.R. Templeton, A cladistic analysis of phenotypic associations with haplotypes inferred from restriction endonuclease mapping or DNA sequencing. V. Analysis of case/control sampling designs: Alzheimer's disease and the apoprotein E locus, Genetics 140 (1995) 403–409.

[18] C.E. Yu, B. Devlin, N. Galloway, E. Loomis, G.D. Schellenberg, ADLAPH: a molecular haplotyping method based on allele-discriminating long-range PCR, Genomics 84 (2004) 600–612.

[19] S.M. Fullerton, et al., Apolipoprotein E variation at the sequence haplotype level: implications for the origin and maintenance of a major human polymorphism, Am. J. Hum. Genet. 67 (2000) 881–900.

[20] A. Rinaldo, et al., Characterization of multilocus linkage disequilibrium, Genet. Epidemiol. 28 (2005) 193–206.

[21] B. Devlin, N. Risch, A comparison of linkage disequilibrium measures for fine-scale mapping, Genomics 29 (1995) 311–322.

[22] A.R. Templeton, et al., Tree scanning: a method for using haplotype trees in phenotype/genotype association studies, Genetics 169 (2005) 441–453.

[23] K.A. Crandall, A.R. Templeton, Empirical tests of some predictions from coalescent theory with applications to intraspecific phylogeny reconstruction, Genetics 134 (1993) 959–969.

[24] A.R. Templeton, E. Boerwinkle, C.F. Sing, A cladistic analysis of phenotypic associations with haplotypes inferred from restriction endonuclease mapping: I. Basic theory and an analysis of alcohol dehydrogenase activity in Drosophila, Genetics 117 (1987) 343–351.

[25] M.J. Bullido, et al., A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia, Nat. Genet. 18 (1998) 69–71.

[26] J.C. Lambert, et al., Pronounced impact of Th1/E47cs mutation compared with −491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's disease, Hum. Mol. Genet. 7 (1998) 1511–1516.

[27] T. Town, et al., The −491A/T apolipoprotein E promoter polymorphism association with Alzheimer's disease: independent risk and linkage disequilibrium with the known APOE polymorphism, Neurosci. Lett. 252 (1998) 95–98.

[28] J.C. Wang, J.M. Kwon, P. Shah, J.C. Morris, A. Goate, Effect of APOE genotype and promoter polymorphism on risk of Alzheimer's disease, Neurology 55 (2000) 1644–1649.

[29] K. Beyer, et al., The Th1/E47cs-G apolipoprotein E (APOE) promoter allele is a risk factor for Alzheimer disease of very late onset, Neurosci. Lett. 326 (2002) 187–190.

[30] J.C. Lambert, et al., Contribution of APOE promoter polymorphisms to Alzheimer's disease risk, Neurology 59 (2002) 59–66.

[31] B.V. North, et al., Further investigation of linkage disequilibrium SNPs and their ability to identify associated susceptibility loci, Ann. Hum. Genet. 68 (2004) 240–248.

[32] C.S. Carlson, et al., Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium, Am. J. Hum. Genet. 74 (2004) 106–120.

[33] C.S. Hanlon, D.C. Rubinsztein, Arginine residues at codons 112 and 158 in the apolipoprotein E gene correspond to the ancestral state in humans, Atherosclerosis 112 (1995) 85–90.

[34] B. Devlin, N. Risch, K. Roeder, Disequilibrium mapping: composite likelihood for pairwise disequilibrium, Genomics 36 (1996) 1–16.

[35] L. Kruglyak, Prospects for whole-genome linkage disequilibrium mapping of common disease genes, Nat. Genet. 22 (1999) 139–144.

[36] A.D. Humphries, et al., Dissection of the mitochondrial import and assembly pathway for human Tom40, J. Biol. Chem. 280 (2005) 11535–11543.

[37] K. Gabriel, B. Egan, T. Lithgow, Tom40, the import channel of the mitochondrial outer membrane, plays an active role in sorting imported proteins, EMBO J. 22 (2003) 2380–2386.

[38] J.P. Blass, A.C. Baker, L. Ko, R.K. Sheu, R.S. Black, Expression of 'Alzheimer antigens' in cultured skin fibroblasts, Arch. Neurol. 48 (1991) 709–717.

[39] J.P. Blass, Brain metabolism and brain disease: is metabolic deficiency the proximate cause of Alzheimer dementia? J. Neurosci. Res. 66 (2001) 851–856.

[40] M. Manczak, B.S. Park, Y. Jung, P.H. Reddy, Differential expression of oxidative phosphorylation genes in patients with Alzheimer's disease: implications for early mitochondrial dysfunction and oxidative damage, Neuromol. Med. 5 (2004) 147–162.

[41] C.A. Marques, et al., Neurotoxic mechanisms caused by the Alzheimer's disease-linked Swedish amyloid precursor protein mutation: oxidative stress, caspases, and the JNK pathway, J. Biol. Chem. 278 (2003) 28294–28302.

[42] W. Sieh, C.E. Yu, T.D. Bird, G.D. Schellenberg, E.M. Wijsman, Accounting for linkage disequilibrium among markers in linkage analysis: impact of haplotype frequency estimation and molecular haplotypes for a gene in a candidate region for Alzheimer's disease, Hum. Hered. 63 (2007) 26–34.

[43] H. Seltman, K. Roeder, B. Devlin, Evolutionary-based association analysis using haplotype data, Genet. Epidemiol. 25 (2003) 48–58.

[44] M. Stephens, N.J. Smith, P. Donnelly, A new statistical method for haplotype reconstruction from population data, Am. J. Hum. Genet. 68 (2001) 978–989.

[45] N. Li, M. Stephens, Modeling linkage disequilibrium and identifying recombination hotspots using single-nucleotide polymorphism data, Genetics 165 (2003) 2213–2233.

[46] D.C. Crawford, et al., Evidence for substantial fine-scale variation in recombination rates across the human genome, Nat. Genet. 36 (2004) 700–706.

[47] M.B. Haviland, R.E. Ferrell, C.F. Sing, Association between common alleles of the low-density lipoprotein receptor gene region and interindividual variation in plasma lipid and apolipoprotein levels in a population-based sample from Rochester, Minnesota, Hum. Genet. 99 (1997) 108–114.

[48] B. Keavney, et al., Measured haplotype analysis of the angiotensin-I converting enzyme gene, Hum. Mol. Genet. 7 (1998) 1745–1751.

[49] F. Soubrier, et al., High-resolution genetic mapping of the ACE-linked QTL influencing circulating ACE activity, Eur. J. Hum. Genet. 10 (2002) 553–561.

[50] R.A. Sweet, et al., Catechol-O-methyltransferase haplotypes are associated with psychosis in Alzheimer disease, Mol. Psychiatry 10 (2005) 1026–1036.